Search clinical trials for: HS-20089

Total 342 results

Shanghai Hansoh Biomedical Co., Ltd

Recruiting

A Study of HS-20089 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Hansoh BioMedical R&D Company

Recruiting

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

China
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age (SLVP016)

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza

Italy
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in T2DM Participants

Type 2 Diabetes

China
Shahid Beheshti University of Medical Sciences

Completed

Antibody Response to Influenza Vaccine in Patients With Sarcoidosis (IVS)

Pulmonary Sarcoidosis

Iran, Islamic Republic of
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383

Cough

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study of HS-10353 in Chinese Participants.

Major Depressive Disorder

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression

Treatment Resistant Depressive Disorder

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383

Cough

China
Qingdao Sino-Cell Biomedicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; West China... and other collaborators

Recruiting

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

Cough
Hansoh BioMedical R&D Company

Not yet recruiting

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia (HS-25-III-01)

Primary Hypercholesterolemia
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction

Healthy

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase 1a Study in Healthy Participants

Healthy
Heartseed Inc.

Recruiting

A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) (LAPiS)

Heart Failure | Ischemic Heart Disease

Japan
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
Hansoh BioMedical R&D Company

Not yet recruiting

A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

Vasomotor Symptoms

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial of HS-10511 in Healthy Subjects

Hypertrophic Cardiomyopathy
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10518 in Healthy Female Participants

Endometriosis
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10353 in Adult Participants With Major Depressive Disorder

Major Depressive Disorder (MDD)
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10517 in Chinese Adult Participants

COVID-19

China
Hansoh BioMedical R&D Company

Recruiting

Study of HS-10384 in Participants of Chinese Postmenopausal Women

Vasomotor Symptoms

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Overweight and Obesity

China
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study (SIMPLIFY-HS)

Cystic Fibrosis

United States
Heat Biologics

Completed

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

Advanced Solid Tumor

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in Healthy Participants

Type 2 Diabetes

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Psoriasis

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostatic Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Herbert Lyerly

Terminated

A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

Solid Tumor

United States
HeadSense Medical
Rigshospitalet, Denmark

Unknown

Comparison of the Non-invasive ICP HeadSense Monitor vs Lumbar CSF Pressure Measurement

Intracranial Hypertension

Denmark, Germany, Netherlands
HeadSense Medical
State Medical Center, Republic of Armenia

Completed

An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Routine Care

Stroke

Armenia
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma
Hansoh BioMedical R&D Company

Recruiting

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Sarcoma | Osteosarcoma

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Advanced Non-Small-Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study of HS-10342 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Atridia Pty Ltd.

Completed

A Phase I Trial of HS-10241 in Solid Tumors

Solid Tumors | Neoplasm

Australia
Universitätsmedizin Mannheim

Withdrawn

HS-PCI in Locally Advanced Adenocarcinoma of the Lung (HIPPO-S)

Adenocarcinoma | Lung Cancer | Lymphatic Metastasis
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours

Carcinoma | Solid Tumor, Adult

China
HeadSense Medical
Oslo University Hospital

Completed

Development and Evaluation of the ICP Waveform Tracing Capabilities and Safety of HS-1000 Device

Brain Injuries | Intracranial Hypertension

Norway
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD

Non-Dialysis-Dependent Chronic Kidney Disease

China
SpinChip Diagnostics ASA
CTC Clinical Trial Consultants AB; Scandinavian Contract Research Organization

Recruiting

SpinChip Hs-cTnI Determination of the 99th Percentile URL (HEAT-3)

Acute Myocardial Infarction

Sweden
SpinChip Diagnostics ASA
University Hospital, Akershus; Scandinavian Contract Research Organization

Recruiting

SpinChip Hs-cTnI Sample Type Validation (HEAT-2)

Acute Myocardial Infarction

Norway
Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China

Search clinical trials for: HS-20089

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations